SFSilas Ramos Furquim

Silas Ramos Furquim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Silas Ramos Furquim has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • FLNC -Related Cardiomyopathies in an Admixed Population: Expanding the Genotype-Phenotype Spectrum and Clinical Correlates

    by Natalia Quintella Sangiorgi Olivetti, Luciana Sacilotto, Julia de Barros Negri Ferreira, Silas Furquim, Márya Pagotti, Bruno Moreira Santos, Marjorie Mizuta, Paula de Mendonça Senra, Giovanna Napolitano, Kelvin Vilalva, et al.

    BACKGROUND: Pathogenic and likely pathogenic variants in filamin C ( FLNC ) cause a broad spectrum of cardiomyopathies. However, available genotype-phenotype data are derived predominantly from European and North American populations, with limited representation of admixed populations. METHODS: We characterized carriers of pathogenic/likely pathogenic FLNC variants identified among 2654 unrelated probands undergoing exome sequencing for suspected inherited cardiomyopathy and their relatives identified through cascade screening. Clinical, electrocardiographic, imaging, genetic, and longitudinal data were analyzed according to cardiomyopathy phenotype and variant class. Genetic ancestry was evaluated. Associations with arrhythmic, heart failure, and composite outcomes were examined in exploratory analyses. RESULTS: The cohort included 97 carriers (58 probands, 39 relatives), of whom 72 had cardiomyopathy and 25 were phenotype-negative at evaluation. Truncating variants predominated among patients with arrhythmogenic cardiomyopathy and dilated cardiomyopathy, whereas missense variants were concentrated among those with hypertrophic cardiomyopathy and restrictive cardiomyopathy. Arrhythmogenic cardiomyopathy and dilated cardiomyopathy were characterized by a greater burden of ventricular arrhythmias, low QRS voltage, systolic dysfunction, and myocardial fibrosis, whereas hypertrophic cardiomyopathy and restrictive cardiomyopathy showed greater wall thickness and more atrial arrhythmias. Twelve pathogenic/likely pathogenic variants absent from gnomAD and ClinVar were identified. Ancestry analysis confirmed heterogeneous genetic backgrounds but detected no ancestry-related differences in variant class or phenotype. In exploratory outcome analyses, nonsustained ventricular tachycardia, low QRS voltage, and late gadolinium enhancement were associated with outcomes. CONCLUSIONS: This deeply phenotyped Brazilian cohort expands the FLNC variant spectrum and supports broad genotype-phenotype associations across an admixed population. Exploratory findings suggest that markers of ventricular arrhythmia and myocardial fibrosis may complement left ventricular ejection fraction in future risk-stratification strategies, although validation in larger, independent cohorts is required.

  • Reverse Remodeling and Genetics: A Review Based on a Clinical Case Description that Challenges Current Evidence and Logic

    by Helena Garcia Betinardi Bernardi, Silas Furquim, Renata Lopes Hames, Jorge Henrique Yoschimoto Koroishi, Jairo Alves Pinheiro, Stevan Krieger Martins

  • Open Access

    Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies

    by Silas Ramos Furquim, Maria Tereza Sampaio de Sousa Lira, Deborah de Sá Pereira Belfort, Bruno Biselli, Paulo Roberto Chizzola, Robinson Tadeu Munhoz, Edimar Alcides Bocchi, Silvia Moreira Ayub-Ferreira

    Cardiac reverse remodelling (RR) is a complex process involving structural and functional recovery of the myocardium, with significant implications for the prognosis of patients with heart failure (HF). This review summarises current concepts, underlying mechanisms, therapeutic strategies, and clinical implications of RR, while distinguishing it from myocardial recovery and remission. Both pharmacological therapies and non-pharmacological interventions have shown potential to induce RR in selected populations. Clinical features, echocardiographic parameters, advanced imaging findings, and biomarkers help stratify patients according to the likelihood of recovery and risk of relapse. The management of HF with improved ejection fraction remains debated. High recurrence rates are seen after therapy discontinuation; however, evidence suggests that partial withdrawal may be safe in specific patient profiles. RR should be considered a central therapeutic goal in HF care, although its extent and stability vary widely. Differentiating between transient improvement, remission under therapy, and true myocardial recovery is critical for guiding long-term treatment decisions, highlighting the importance of individualised follow-up.


  • Open Access

    Remodelamento Reverso e Genética: Uma Revisão Baseada na Descrição de um Caso Clínico que Foge à Lógica e Vai de Encontro às Evidências

    by Helena Garcia Betinardi Bernardi, Silas Furquim, Renata Lopes Hames, Jorge Henrique Yoschimoto Koroishi, Jairo Alves Pinheiro Junior, Stevan Krieger Martins

    O remodelamento cardíaco, presente na insuficiência cardíaca (IC), é um processo biológico compensatório após uma agressão inicial ao miocárdio que gradualmente se torna desadaptativo, gerando deterioração clínica e a IC crônica. Cada vez mais abordado, o remodelamento reverso (RR) ocorre quando há recuperação da geometria e/ou função do ventrículo esquerdo em resposta ao tratamento empregado, aproximando-se da estrutura cardíaca normal e sendo associado a melhor prognóstico. Sexo feminino, etiologia não isquêmica, IC leve a moderada, menor carga fibrótica, pressão arterial elevada tolerando otimização de medicamentos, menor duração da doença e função renal preservada são fatores associados ao RR. No entanto, o crescente conhecimento do aspecto genético na etiologia da IC traz insights importantes sobre o comportamento desse componente na resposta ao tratamento e ao prognóstico. Para ilustrar e discutir estes temas de emergente relevância, relata-se um caso de IC avançada envolvendo conceitos de RR, variante genética e o manejo atualmente recomendado.

  • Open Access

    Explorando o Papel das Variantes do ALPK3 em Cardiomiopatias Hipertróficas e Dilatadas

    by Fernanda Almeida Andrade, Bruno de Oliveira Stephan, Silas Ramos Furquim, Bianca Domit Werner Linnenkamp, Lucas Vieira Lacerda Pires, Vitória Pelegrino Do Val, Nara Alves Buriti, Layara Fernanda Vicente Pereira Lipari, Vinícius Machado Correia, José Eduardo Krieger

    As variantes do gene ALPK3 (proteína alfa-quinase 3), em especial as variantes truncadas (ALPK3tv), têm sido associadas à cardiomiopatia hipertrófica (CMH) e à cardiomiopatia dilatada (CMD), contribuindo para a variabilidade fenotípica e para resultados clínicos graves. A CMH é caracterizada por uma hipertrofia ventricular esquerda não atribuível a outras causas, sendo uma condição genética comum, ligada frequentemente a variantes patogênicas em genes de sarcômeros. No entanto, em aproximadamente 40% dos casos, os testes genéticos não são capazes de identificar uma variante causal, o que sugere o envolvimento de genes não sarcoméricos, como o ALPK3. Estudos recentes revelam que a ALPK3tv bialélica está associada à cardiomiopatia grave de início precoce. Os pacientes podem apresentar uma progressão clínica da CMD na infância para a CMH, com função sistólica prejudicada na vida adulta. Nesses indivíduos, o fenótipo da CMH é caracterizado, em geral, por fibrose miocárdica extensa, padrões apicais ou concêntricos de hipertrofia ventricular esquerda e baixa prevalência de obstrução do trato de saída do ventrículo esquerdo. Os portadores de ALPK3tv também correm o risco de desenvolver disfunção miocárdica progressiva, insuficiência cardíaca e, em alguns casos, morte cardíaca súbita. Os mecanismos moleculares subjacentes à cardiomiopatia relacionada ao ALPK3 envolvem a interrupção de proteínas estruturais e regulatórias, como as miomesinas, essenciais para a integridade do sarcômero e o controle da força dos cardiomiócitos. A descoberta das variantes do gene ALPK3 em populações sub-representadas destaca a importância da pesquisa genética em diversas coortes. A compreensão das consequências clínicas e moleculares das variantes do gene ALPK3 pode resultar em abordagens diagnósticas e terapêuticas mais precisas para cardiomiopatias associadas a esse gene.

  • Open Access

    Desvendando um Enigma Genético: Hipertrofia Assimétrica em um Receptor de Transplante Cardíaco Relacionado à Síndrome de Birt-Hogg-Dubé

    by Silas Ramos Furquim, Lucas Vieira Lacerda Pires, Nara Alves Buriti, Mariana Lombardi Peres de Carvalho, Emanuelle Leonilia Marques, Bianca Domit Werner Linnenkamp, Luciana Sacilotto, Fabiana G. Marcondes-Braga, Iascara Wozniak de Campos, Luis Fernando Bernal da Costa Seguro, et al.

    Resumo Um caso de um homem de 54 anos que se submeteu a um transplante cardíaco com hipertrofia assimétrica precoce não relacionada à rejeição. A análise genética do doador revelou uma variante no gene da foliculina, associada à síndrome de Birt-Hogg-Dubé. O rastreamento da família do doador identificou uma hipertrofia similar e a mesma variante genética no pai do doador. Embora a avaliação genética dos tecidos dos doadores não seja realizada rotineiramente, ela pode ser crucial para compreender alterações não relacionadas ao procedimento do transplante e identificar carreadores de variantes patogênicas.

  • Open Access

    Unveiling the Genetic Puzzle: Asymmetric Hypertrophy in a Heart Transplant Recipient Linked to Birt-Hogg-Dubé Syndrome

    by Silas Ramos Furquim, Lucas Vieira Lacerda Pires, Nara Alves Buriti, Mariana Lombardi Peres de Carvalho, Emanuelle Leonilia Marques, Bianca Domit Werner Linnenkamp, Luciana Sacilotto, Fabiana G. Marcondes-Braga, Iascara Wozniak de Campos, Luis Fernando Bernal da Costa Seguro, et al.

    A case of a 54-year-old man who underwent a heart transplant with early asymmetric hypertrophy unrelated to rejection. Donor’s genetic analysis revealed a variant in folliculin gene, associated with Birt-Hogg-Dubé Syndrome. Screening of the donor’s family uncovered a similar hypertrophy and same genetic variant in the donor’s father. Although genetic evaluation of donors’ tissues is not routine, it can be crucial for understanding changes unrelated to the transplant procedure and identifying carriers of pathogenic variants.

  • Open Access

    Exploring the Role of ALPK3 Variants in Hypertrophic and Dilated Cardiomyopathies

    by Fernanda Almeida Andrade, Bruno de Oliveira Stephan, Silas Ramos Furquim, Bianca Domit Werner Linnenkamp, Lucas Vieira Lacerda Pires, Vitória Pelegrino Do Val, Nara Alves Buriti, Layara Fernanda Vicente Pereira Lipari, Vinícius Machado Correia, José Eduardo Krieger

    Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such [...] Abstract Alpha-protein kinase 3 (ALPK3) variants, particularly truncating mutations (ALPK3tv), have been associated with both hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), contributing to phenotypic variability and severe clinical outcomes. HCM is characterized by left ventricular hypertrophy (LVH) not attributable to other causes and is a common genetic disorder, often linked to pathogenic variants in sarcomeric genes. However, clinical genetic testing fails to identify a causative mutation in approximately 40% of the cases, suggesting the involvement of non-sarcomeric genes such

  • Open Access

    Predictors of Sustained Reverse Remodelling in Patients with Heart Failure with Reduced Ejection Fraction

    by Silas Ramos Furquim, Edimar Alcides Bocchi, Maria Tereza Sampaio Lira de Sousa, Mauro Rogerio Wanderley de Barros, Daniel Catto de Marchi, Pamela Camara Maciel, Andre Zimerman, Felix Jose Alvarez Ramires, Luciano Nastari, Bruno Biselli, et al.

    Background: Patients with heart failure with reduced ejection fraction (HFrEF) who achieve reverse remodelling (RR) can experience a new decrease in ejection fraction (EF), and the predictors of sustained RR (SRR) are not completely understood. Objectives: The study aims to identify predictors of SRR in patients with HFrEF after an increase in EF and evaluate SRR prognosis. Methods: In this retrospective, observational study, we evaluated a real-life cohort of patients with HFrEF and ≥2 consecutive echocardiograms, divided according to left ventricular EF (LVEF) trajectory: no RR (NRR: 3/3 LVEF measurements < 40%), non-SRR (NSRR: second LVEF ≥ 40%, third LVEF < 40%), and SRR (SRR: second and third LVEF ≥ 40%). Results: We included 3628 of 8072 assessed HF patients in the analysis, with mean age 56.2 (±13.4) years, 64.4% male and 77.7% New York Heart Association (NYHA) I–II. Improved EF was observed for 1342 (37%) patients. Among those who achieved RR, 310 (23%) were NSRR, and 1032 (77%) were SRR. The mean (±SE) survival after the second echocardiogram was 10.6 (±0.2) years. The SRR group had the longest survival (12.2 ± 0.3 years), followed by the NSRR (10.6 ± 0.5) and NRR (9.8 ± 0.2 years) groups (P < 0.001). According to logistic multivariable regression, second LVEF [odds ratio (OR) = 1.06, confidence interval (CI) = 1.03–1.90, P < 0.001], second left ventricular end-systolic diameter (LVESD) (OR = 0.93, CI = 0.90–0.96, P < 0.001), second IV septum thickness (OR = 1.12, CI = 1.03–1.23, P = 0.012), systolic blood pressure (OR = 1.01, CI = 1.00–1.02, P = 0.014), NYHA I–II (OR = 1.86, CI = 1.27–2.74, P = 0.001) and furosemide non-use (OR = 1.87, CI = 1.27–2.74, P < 0.001) independently predicted SRR. Conclusions: Patients with greater EF increases and LVESD reductions at EF recovery, greater septum thickness, higher blood pressure, no need for diuretics and NYHA I/II maintenance had the best chance of maintaining recovered ventricular function.


  • Open Access

    O Papel das Variantes no Gene TTN na Cardiomiopatia Dilatada

    by Silas Ramos Furquim, Paula de Mendonça Senra, Bianca Domit Werner Linnenkamp, Kelvin Henrique Vilalva, Marjorie Hayashida Mizuta, Bruno Moreira dos Santos, Bruno de Oliveira Stephan, Elisangela Aparecida da Silva, Nara Alves Buriti, Vitória Pelegrino Do Val, et al.

    A titina, codificada pelo gene TTN, é a maior proteína humana, essencial para a manutenção da estabilidade das células musculares e regulação da contração miocárdica. As variantes truncadas do TTN (TTNtv) têm sido consideradas a causa genética mais comum de cardiomiopatia dilatada (CMD), respondendo por até 25% dos casos familiares e 18% dos casos esporádicos. Esta revisão examina a relação complexa entre as variantes no gene TTN e a CMD, destacando os desafios impostos pela penetrância incompleta e a expressividade variável. Embora as variantes truncadas, principalmente na região da banda A, estejam ligadas à CMD, nem todos os portadores apresentam sintomas clínicos, indicando a influência de fatores genéticos e ambientais adicionais. Além disso, discutimos as implicações prognósticas das variantes no gene TTN, que, apesar dos resultados clínicos semelhantes a outros casos de CMD, demonstram uma taxa maior de remodelação reverso em resposta ao tratamento da insuficiência cardíaca. Estratégias terapêuticas emergentes, que visam mecanismos moleculares subjacentes das variantes no gene TTN, incluindo inibidores de mTOR e edição genética baseada em CRISPR, oferecem possibilidades promissoras para um tratamento personalizado. Compreender os fundamentos genéticos da CMD relacionada ao TTN é crucial para melhorar o diagnóstico, o rastreamento familiar e os resultados terapêuticos, abrindo caminho para um manejo mais eficaz desse quadro complexo.